The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells

被引:25
作者
Baptiste N. [1 ]
Friedlander P. [1 ]
Chen X. [1 ]
Prives C. [1 ]
机构
[1] Department of Biological Sciences, Columbia University, New York
关键词
Anti-neoplastics; Apoptosis; p53; Proline-rich domain;
D O I
10.1038/sj.onc.1205015
中图分类号
学科分类号
摘要
In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracycline-regulated promoter. In these cells the induction of wild-type p53 leads to significant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sufficient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also effectively increase cell death when a transcriptionally-defective p53, p53[gln22ser23], is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53[gln22ser23]. Our results with 5-FU thus show that genetically separable functions of p53 are involved in its ability to respond to DNA-damaging agents to induce apoptosis. Notably as well, deleting the C-terminal 30 amino acids of p53 does not affect this cooperative effect with DNA-damaging agents. By contrast, a p53 mutant lacking the PXXP-domain between residues 60-90, while at least partially transcriptionally-competent, cannot be rendered apoptotic by any compounds that we tested. Thus the PXXP domain provides an essential component of the ability of p53 to respond to DNA-damaging agents to cause cell death.
引用
收藏
页码:9 / 21
页数:12
相关论文
共 115 条
  • [71] Oren M., J. Biol. Chem., 274, pp. 36031-36034, (1999)
  • [72] Owen-Schaub L.B., Zhang W., Cusack J.C., Angelo L.S., Santee S.M., Fujiwara T., Roth J.A., Deisseroth A.B., Zhang W.W., Kruzel E., Radinsky R., Mol. Cell. Biol., 15, pp. 3032-3040, (1995)
  • [73] Parks D., Bolinger R., Mann K., Nucleic Acids Res., 25, pp. 1289-1295, (1997)
  • [74] Peller S., Semin. Cancer Biol., 8, pp. 379-387, (1998)
  • [75] Polyak K., Waldman T., He T.C., Kinzler K.W., Vogelstein B., Genes Dev., 10, pp. 1945-1952, (1996)
  • [76] Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B., Nature, 389, pp. 300-305, (1997)
  • [77] Prives C., Cell, 95, pp. 5-8, (1998)
  • [78] Prives C., Hall P.A., J. Pathol., 187, pp. 112-126, (1999)
  • [79] Reed M., Woelker B., Wang P., Wang Y., Anderson M.E., Tegtmeyer P., Proc. Natl. Acad. Sci. USA, 92, pp. 9455-9459, (1995)
  • [80] Resnitzky D., Gossen M., Bujard H., Reed S.I., Mol. Cell. Biol., 14, pp. 1669-1679, (1994)